Seaport Therapeutics Inc. (SPTX)

$19.84 -1.16 (-5.52%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 4,690,615
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in develo...

Industry: Biotechnology
Sector: Healthcare
Phone: (617) 807-4062
Address:
101 Seaport Blvd., Floor 12, Boston, United States
BioTuesdays
BioTuesdays Jun. 8 at 5:02 PM
$SPTX has announced positive data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. https://biotuesdays.com/2026/06/08/seaport-reports-positive-dose-data-from-trial-of-glyphago-for-anxiety/
0 · Reply
biodoc1
biodoc1 May. 29 at 3:09 PM
$SPTX This company looks promising. Lead drugs with recognized effective MOA but bioavailability problems that could be overcome with glyph technology. Experienced management team, several from Karuna/Puretech. They efficiently developed KarXT from early phase to approval and are well connected to Psych clinical research PIs and KOLs as well as Wall Street. Plenty of cash for development of lead and backup drugs. .
1 · Reply
IsabellaDC
IsabellaDC May. 28 at 2:50 PM
All time high. My baby is back in the board. :) $UMAC $CGCT $TOYO $SPTX $SNDK and so on... (tags blue--long and green--swing own)
0 · Reply
TATTED_KEN
TATTED_KEN May. 14 at 4:35 PM
$SPTX so far so good Sitting in my IRA. Long-term target $50 🎯
0 · Reply
unbreakable01
unbreakable01 May. 6 at 4:30 PM
$SPTX buying this now, will reap a ton on returns.
0 · Reply
amazingcrwns
amazingcrwns May. 6 at 3:14 PM
$SPTX I wonder if they'll have better luck than Lipocine. Seems like a similar drug delivery technology. I don't know if Glyph has any advantages or disadvantages compared to Lip'ral, but I'm curious how their drug trials will play out. I'm not ready to invest, but good luck to those that do.
0 · Reply
TATTED_KEN
TATTED_KEN May. 5 at 1:03 PM
$SPTX adding to my IRA. 10% owner just filed for 1.1M shares at a $20M valuation. I see this moving over $50 soon.
0 · Reply
theflynews
theflynews May. 4 at 3:49 PM
Opening Day: Pershing Square listings open soft in market debut - $SPTX - https://thefly.com/SPTX
0 · Reply
cavinsin
cavinsin May. 3 at 4:40 PM
$SPTX I am very confident to invest in this company Foprmer CEO of Intra Cellular Therapies, Sharon Mates has joined this team, Check what ITCI did in 5 years under her command, Amazing, from $10 to $ 130 GL to all
0 · Reply
Latest News on SPTX
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Jun 9, 2026, 2:00 AM EDT - 8 days ago

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year

2026-06-08T11:18:52.000Z - 9 days ago

Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year

Seaport Therapeutics sees cash runway into 2029

2026-06-08T11:17:50.000Z - 9 days ago

Seaport Therapeutics sees cash runway into 2029

Seaport announces data from MAD part of Phase 1 trial of GlyphAgo

2026-06-08T11:05:07.000Z - 9 days ago

Seaport announces data from MAD part of Phase 1 trial of GlyphAgo

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Jun 8, 2026, 7:05 AM EDT - 9 days ago

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Jun 8, 2026, 7:00 AM EDT - 9 days ago

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Earnings release: Q1 2026

Jun 8, 2026, 7:00 AM EDT - 9 days ago

Seaport Therapeutics Earnings release: Q1 2026

Seaport Therapeutics Quarterly report: Q1 2026

Jun 8, 2026, 7:00 AM EDT - 9 days ago

Seaport Therapeutics Quarterly report: Q1 2026

Seaport Therapeutics Slides: Corporate presentation

Jun 6, 2026, 7:00 AM EDT - 11 days ago

Seaport Therapeutics Slides: Corporate presentation

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Jun 1, 2026, 7:00 AM EDT - 16 days ago

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Seaport Therapeutics initiated with an Outperform at Leerink

2026-05-26T10:24:11.000Z - 22 days ago

Seaport Therapeutics initiated with an Outperform at Leerink

Seaport Therapeutics initiated with a Buy at Citi

2026-05-26T10:10:50.000Z - 22 days ago

Seaport Therapeutics initiated with a Buy at Citi

Seaport Therapeutics initiated with a Buy at Stifel

2026-05-26T09:16:15.000Z - 22 days ago

Seaport Therapeutics initiated with a Buy at Stifel

Seaport Therapeutics initiated with an Overweight at JPMorgan

2026-05-26T09:05:05.000Z - 22 days ago

Seaport Therapeutics initiated with an Overweight at JPMorgan

Seaport Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

2026-05-26T08:25:42.000Z - 22 days ago

Seaport Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Opening Day: Pershing Square listings open soft in market debut

2026-05-04T15:51:33.000Z - 6 weeks ago

Opening Day: Pershing Square listings open soft in market debut

ACGC ARCL AVLN BIP BWIV CAII COAG

Seaport Therapeutics opens at $21, IPO priced at $18 per share

2026-05-01T16:35:17.000Z - 6 weeks ago

Seaport Therapeutics opens at $21, IPO priced at $18 per share

Seaport Therapeutics 14.2M share IPO priced at $18.00

2026-05-01T11:26:48.000Z - 6 weeks ago

Seaport Therapeutics 14.2M share IPO priced at $18.00

Seaport Therapeutics raises about $255 million in upsized IPO

Apr 30, 2026, 11:25 PM EDT - 6 weeks ago

Seaport Therapeutics raises about $255 million in upsized IPO

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

Apr 30, 2026, 9:55 PM EDT - 6 weeks ago

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

Seaport Therapeutics prices 14.6M share IPO a $18, top of range, Bloomberg says

2026-04-30T23:35:25.000Z - 6 weeks ago

Seaport Therapeutics prices 14.6M share IPO a $18, top of range, Bloomberg says

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO

Apr 27, 2026, 6:41 AM EDT - 7 weeks ago

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO

Seaport Therapeutics IPO Registration Document (S-1)

Apr 10, 2026, 4:01 PM EDT - 2 months ago

Seaport Therapeutics IPO Registration Document (S-1)

Seaport Therapeutics IPO Registration Document (S-1)

Apr 10, 2026, 2:07 PM EDT - 2 months ago

Seaport Therapeutics IPO Registration Document (S-1)

BioTuesdays
BioTuesdays Jun. 8 at 5:02 PM
$SPTX has announced positive data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. https://biotuesdays.com/2026/06/08/seaport-reports-positive-dose-data-from-trial-of-glyphago-for-anxiety/
0 · Reply
biodoc1
biodoc1 May. 29 at 3:09 PM
$SPTX This company looks promising. Lead drugs with recognized effective MOA but bioavailability problems that could be overcome with glyph technology. Experienced management team, several from Karuna/Puretech. They efficiently developed KarXT from early phase to approval and are well connected to Psych clinical research PIs and KOLs as well as Wall Street. Plenty of cash for development of lead and backup drugs. .
1 · Reply
IsabellaDC
IsabellaDC May. 28 at 2:50 PM
All time high. My baby is back in the board. :) $UMAC $CGCT $TOYO $SPTX $SNDK and so on... (tags blue--long and green--swing own)
0 · Reply
TATTED_KEN
TATTED_KEN May. 14 at 4:35 PM
$SPTX so far so good Sitting in my IRA. Long-term target $50 🎯
0 · Reply
unbreakable01
unbreakable01 May. 6 at 4:30 PM
$SPTX buying this now, will reap a ton on returns.
0 · Reply
amazingcrwns
amazingcrwns May. 6 at 3:14 PM
$SPTX I wonder if they'll have better luck than Lipocine. Seems like a similar drug delivery technology. I don't know if Glyph has any advantages or disadvantages compared to Lip'ral, but I'm curious how their drug trials will play out. I'm not ready to invest, but good luck to those that do.
0 · Reply
TATTED_KEN
TATTED_KEN May. 5 at 1:03 PM
$SPTX adding to my IRA. 10% owner just filed for 1.1M shares at a $20M valuation. I see this moving over $50 soon.
0 · Reply
theflynews
theflynews May. 4 at 3:49 PM
Opening Day: Pershing Square listings open soft in market debut - $SPTX - https://thefly.com/SPTX
0 · Reply
cavinsin
cavinsin May. 3 at 4:40 PM
$SPTX I am very confident to invest in this company Foprmer CEO of Intra Cellular Therapies, Sharon Mates has joined this team, Check what ITCI did in 5 years under her command, Amazing, from $10 to $ 130 GL to all
0 · Reply